Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Coya Therapeutics (COYA) Enterprise Value (2022 - 2025)

Coya Therapeutics' Enterprise Value history spans 4 years, with the latest figure at -$28.1 million for Q3 2025.

  • For Q3 2025, Enterprise Value rose 9.52% year-over-year to -$28.1 million; the TTM value through Sep 2025 reached -$28.1 million, up 9.52%, while the annual FY2024 figure was -$38.3 million, 17.51% down from the prior year.
  • Enterprise Value for Q3 2025 was -$28.1 million at Coya Therapeutics, up from -$29.8 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$5.9 million in Q4 2022 and bottomed at -$38.3 million in Q4 2024.
  • The 4-year median for Enterprise Value is -$30.4 million (2024), against an average of -$26.2 million.
  • The largest annual shift saw Enterprise Value tumbled 449.86% in 2023 before it increased 18.7% in 2025.
  • A 4-year view of Enterprise Value shows it stood at -$5.9 million in 2022, then crashed by 449.86% to -$32.6 million in 2023, then decreased by 17.51% to -$38.3 million in 2024, then increased by 26.71% to -$28.1 million in 2025.
  • Per Business Quant, the three most recent readings for COYA's Enterprise Value are -$28.1 million (Q3 2025), -$29.8 million (Q2 2025), and -$35.5 million (Q1 2025).